Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Microbiota Composition Is Different Both between IBD Subtypes and Geographic Locations
3.2. Higher Usage of Resection, Medications and Supplements among Canadian Participants
3.3. Polypharmacy Associated with the Disease-Associated Microbiota Shift in Crohn’s Disease
3.4. Treatment Explains More Variation in Microbial Composition Than IBD-Subtype
3.5. Disease-Associated Bacteria Are Less Affected by Medications Than Health-Associated Bacteria
3.6. Additive Effects of Multiple Medications Amplify the Effect of IBD-Subtype on Gut Microbiota
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ryan, F.J.; Ahern, A.M.; Fitzgerald, R.S.; Laserna-Mendieta, E.J.; Power, E.M.; Clooney, A.G.; O’Donoghue, K.W.; McMurdie, P.J.; Iwai, S.; Crits-Christoph, A.; et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat. Commun. 2020, 11, 1512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alam, M.T.; Amos, G.C.A.; Murphy, A.R.J.; Murch, S.; Wellington, E.M.H.; Arasaradnam, R.P. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020, 12, 1. [Google Scholar] [CrossRef] [PubMed]
- Khan, I.; Ullah, N.; Zha, L.; Bai, Y.; Khan, A.; Zhao, T.; Che, T.; Zhang, C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens 2019, 8, 126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aldars-Garcia, L.; Chaparro, M.; Gisbert, J.P. Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms 2021, 9, 977. [Google Scholar] [CrossRef] [PubMed]
- Pittayanon, R.; Lau, J.T.; Leontiadis, G.I.; Tse, F.; Yuan, Y.; Surette, M.; Moayyedi, P. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology 2020, 158, 930–946.e1. [Google Scholar] [CrossRef] [PubMed]
- Elvers, K.T.; Wilson, V.J.; Hammond, A.; Duncan, L.; Huntley, A.L.; Hay, A.D.; van der Werf, E.T. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: A systematic review. BMJ Open 2020, 10, e035677. [Google Scholar] [CrossRef]
- Oh, B.; Boyle, F.; Pavlakis, N.; Clarke, S.; Guminski, A.; Eade, T.; Lamoury, G.; Carroll, S.; Morgia, M.; Kneebone, A.; et al. Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Front. Oncol. 2021, 11, 706331. [Google Scholar] [CrossRef]
- Maier, L.; Pruteanu, M.; Kuhn, M.; Zeller, G.; Telzerow, A.; Anderson, E.E.; Brochado, A.R.; Fernandez, K.C.; Dose, H.; Mori, H.; et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018, 555, 623–628. [Google Scholar] [CrossRef]
- Sargautiene, V.; Ligere, R.; Kalniņa, I.; Jākobsone, I.; Nikolajeva, V.; Derovs, A. The Effect of 5-Aminosalicylic Acid on Intestinal Microbiota. Proc. Latv. Acad. Sci. Sect. B Nat. Exact Appl. Sci. 2020, 74, 53–57. [Google Scholar] [CrossRef]
- Huang, E.Y.; Inoue, T.; Leone, V.A.; Dalal, S.; Touw, K.; Wang, Y.W.; Musch, M.W.; Theriault, B.; Higuchi, K.; Donovan, S.; et al. Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases. Inflamm. Bowel Dis. 2015, 21, 963–972. [Google Scholar] [CrossRef]
- Swidsinski, A.; Loening-Baucke, V.; Bengmark, S.; Lochs, H.; Dorffel, Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm. Bowel Dis. 2007, 13, 51–56. [Google Scholar] [CrossRef] [PubMed]
- Letertre, M.P.M.; Munjoma, N.; Wolfer, K.; Pechlivanis, A.; McDonald, J.A.K.; Hardwick, R.N.; Cherrington, N.J.; Coen, M.; Nicholson, J.K.; Hoyles, L.; et al. A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague-Dawley Rats. J. Proteome Res. 2020, 19, 3326–3339. [Google Scholar] [CrossRef] [PubMed]
- Magnusson, M.K.; Strid, H.; Sapnara, M.; Lasson, A.; Bajor, A.; Ung, K.A.; Ohman, L. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. J. Crohn’s Colitis 2016, 10, 943–952. [Google Scholar] [CrossRef] [PubMed]
- Franzin, M.; Stefancic, K.; Lucafo, M.; Decorti, G.; Stocco, G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021, 10, 211. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Chen, N.; Wu, Z.; Song, Y.; Zhang, Y.; Wu, N.; Zhang, F.; Ren, X.; Liu, Y. 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front. Microbiol. 2018, 9, 1274. [Google Scholar] [CrossRef] [PubMed]
- Vich Vila, A.; Collij, V.; Sanna, S.; Sinha, T.; Imhann, F.; Bourgonje, A.R.; Mujagic, Z.; Jonkers, D.M.A.E.; Masclee, A.A.M.; Fu, J.; et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 2020, 11, 362. [Google Scholar] [CrossRef] [Green Version]
- Zimmermann, M.; Zimmermann-Kogadeeva, M.; Wegmann, R.; Goodman, A.L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019, 570, 462–467. [Google Scholar] [CrossRef]
- Klunemann, M.; Andrejev, S.; Blasche, S.; Mateus, A.; Phapale, P.; Devendran, S.; Vappiani, J.; Simon, B.; Scott, T.A.; Kafkia, E.; et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature 2021, 597, 533–538. [Google Scholar] [CrossRef]
- Clooney, A.G.; Bernstein, C.N.; Leslie, W.D.; Vagianos, K.; Sargent, M.; Laserna-Mendieta, E.J.; Claesson, M.J.; Targownik, L.E. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharmacol. Ther. 2016, 43, 974–984. [Google Scholar] [CrossRef] [Green Version]
- Weersma, R.K.; Zhernakova, A.; Fu, J. Interaction between drugs and the gut microbiome. Gut 2020, 69, 1510–1519. [Google Scholar] [CrossRef]
- Vieira-Silva, S.; Falony, G.; Belda, E.; Nielsen, T.; Aron-Wisnewsky, J.; Chakaroun, R.; Forslund, S.K.; Assmann, K.; Valles-Colomer, M.; Nguyen, T.T.D.; et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020, 581, 310–315. [Google Scholar] [CrossRef] [PubMed]
- Tropini, C.; Moss, E.L.; Merrill, B.D.; Ng, K.M.; Higginbottom, S.K.; Casavant, E.P.; Gonzalez, C.G.; Fremin, B.; Bouley, D.M.; Elias, J.E.; et al. Transient Osmotic Perturbation Causes Long-Term Alteration to the Gut Microbiota. Cell 2018, 173, 1742–1754.e17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Forslund, K.; Hildebrand, F.; Nielsen, T.; Falony, G.; Le Chatelier, E.; Sunagawa, S.; Prifti, E.; Vieira-Silva, S.; Gudmundsdottir, V.; Pedersen, H.K.; et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015, 528, 262–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, Y.-T.; Lin, T.-Y.; Hung, S.-C.; Liu, P.-Y.; Hung, W.-C.; Tsai, W.-C.; Tsai, Y.-C.; Delicano, R.A.; Chuang, Y.-S.; Kuo, M.-C.; et al. Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers. J. Pers. Med. 2021, 11, 198. [Google Scholar] [CrossRef] [PubMed]
- Tuteja, S.; Ferguson, J.F. Gut Microbiome and Response to Cardiovascular Drugs. Circ. Genom. Precis. Med. 2019, 12, e002314. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Munoz-Bellido, J.L.; Munoz-Criado, S.; Garìa-Rodrìguez, J.A. Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 2000, 14, 177–180. [Google Scholar] [CrossRef]
- Falony, G.; Joossens, M.; Vieira-Silva, S.; Wang, J.; Darzi, Y.; Faust, K.; Kurilshikov, A.; Bonder, M.J.; Valles-Colomer, M.; Vandeputte, D.; et al. Population-level analysis of gut microbiome variation. Science 2016, 352, 560–564. [Google Scholar] [CrossRef]
- Forslund, S.K.; Chakaroun, R.; Zimmermann-Kogadeeva, M.; Marko, L.; Aron-Wisnewsky, J.; Nielsen, T.; Moitinho-Silva, L.; Schmidt, T.S.B.; Falony, G.; Vieira-Silva, S.; et al. Combinatorial, additive and dose-dependent drug-microbiome associations. Nature 2021, 600, 500–505. [Google Scholar] [CrossRef]
- Clooney, A.G.; Eckenberger, J.; Laserna-Mendieta, E.; Sexton, K.A.; Bernstein, M.T.; Vagianos, K.; Sargent, M.; Ryan, F.J.; Moran, C.; Sheehan, D.; et al. Ranking microbiome variance in inflammatory bowel disease: A large longitudinal intercontinental study. Gut 2021, 70, 499. [Google Scholar] [CrossRef]
- Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.; Glockner, F.O. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 2013, 41, D590–D596. [Google Scholar] [CrossRef]
- Schloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hollister, E.B.; Lesniewski, R.A.; Oakley, B.B.; Parks, D.H.; Robinson, C.J.; et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 2009, 75, 7537–7541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allard, G.; Ryan, F.J.; Jeffery, I.B.; Claesson, M.J. SPINGO: A rapid species-classifier for microbial amplicon sequences. BMC Bioinform. 2015, 16, 324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403–410. [Google Scholar] [CrossRef]
- WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment; Norwegian Institute of Public Health: Oslo, Norway, 2021. [Google Scholar]
- Sica, G.S.; Biancone, L. Surgery for inflammatory bowel disease in the era of laparoscopy. World J. Gastroenterol. 2013, 19, 2445–2448. [Google Scholar] [CrossRef] [Green Version]
- Fang, X.; Vazquez-Baeza, Y.; Elijah, E.; Vargas, F.; Ackermann, G.; Humphrey, G.; Lau, R.; Weldon, K.C.; Sanders, J.G.; Panitchpakdi, M.; et al. Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity (vol 27, pg 1368, 2021). Inflamm. Bowel Dis. 2021, 27, 1368. [Google Scholar]
- Drescher, L.S.; Thiele, S.; Mensink, G.B. A new index to measure healthy food diversity better reflects a healthy diet than traditional measures. J. Nutr. 2007, 137, 647–651. [Google Scholar] [CrossRef] [Green Version]
- Lin, J.F.; Chen, J.M.; Zuo, J.H.; Yu, A.; Xiao, Z.J.; Deng, F.H.; Nie, B.; Jiang, B. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm. Bowel Dis. 2014, 20, 1407–1415. [Google Scholar] [CrossRef]
- Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: New York, NY, USA, 2016. [Google Scholar]
- Gloor, G.B.; Macklaim, J.M.; Pawlowsky-Glahn, V.; Egozcue, J.J. Microbiome Datasets Are Compositional: And This Is Not Optional. Front. Microbiol. 2017, 8, 2224. [Google Scholar] [CrossRef] [Green Version]
- Palarea-Albaladejo, J.; Martín-Fernández, J.A. zCompositions—R package for multivariate imputation of left-censored data under a compositional approach. Chemom. Intell. Lab. Syst. 2015, 143, 85–96. [Google Scholar] [CrossRef]
- Quinn, T.P.; Erb, I.; Gloor, G.; Notredame, C.; Richardson, M.F.; Crowley, T.M. A field guide for the compositional analysis of any-omics data. GigaScience 2019, 8, giz107. [Google Scholar] [CrossRef]
- Aitchison, J.; Barceló-Vidal, C.; Martín-Fernández, J.A.; Pawlowsky-Glahn, V. Logratio Analysis and Compositional Distance. Math. Geol. 2000, 32, 271–275. [Google Scholar] [CrossRef]
- McMurdie, P.J.; Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS ONE 2013, 8, e61217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oksanen, J.; Blanchet, F.G.; Kindt, R.; Legendre, P.; Minchin, P.; O’hara, R.; Simpson, G.; Solymos, P.; Stevens, M.H.H.; Wagner, H. Community Ecology Package. R Package Version 2.2-0. Available online: http://CRAN.Rproject.org/package=vegan (accessed on 1 April 2022).
- Chao, A.; Gotelli, N.J.; Hsieh, T.C.; Sander, E.L.; Ma, K.H.; Colwell, R.K.; Ellison, A.M. Rarefaction and extrapolation with Hill numbers: A framework for sampling and estimation in species diversity studies. Ecol. Monogr. 2014, 84, 45–67. [Google Scholar] [CrossRef] [Green Version]
- Fernandes, A.D.; Macklaim, J.M.; Linn, T.G.; Reid, G.; Gloor, G.B. ANOVA-Like Differential Expression (ALDEx) Analysis for Mixed Population RNA-Seq. PLoS ONE 2013, 8, e67019. [Google Scholar] [CrossRef] [PubMed]
- von Lampe, F. Goeveg R-Package. In Functions for Community Data and Ordinations. A Collection of Functions Useful in (Vegetation) Community Analyses and Ordinations. 2021. Available online: https://github.com/fvlampe/goeveg (accessed on 1 April 2022).
- Moitinho-Silva, L.; Forslund, S.K.; Chakaroun, R.; Zimmermann-Kogadeeva, M.; Markó, L.; Aron-Wisnewsky, J.; Nielsen, T.; Birkner, T. Grp-bork/vpthemall: Release of Vpthemall—Assistant Functions for Variation Partition with dbRDA Method. Available online: https://zenodo.org/record/6242715#.Yzra43bMInI (accessed on 1 April 2022).
- Forslund, S.K.; Chakaroun, R.; Zimmermann-Kogadeeva, M.; Markó, L.; Aron-Wisnewsky, J.; Nielsen, T.; Birkner, T. Data Analysis Pipeline for Investigating Drug-Host-Microbiome Relationships in Cardiometabolic Disease (MetaCardis Cohort). Available online: https://zenodo.org/record/5463864#.YzrbsHbMInI (accessed on 1 April 2022).
- Benjamini, Y.; Drai, D.; Elmer, G.; Kafkafi, N.; Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125, 279–284. [Google Scholar] [CrossRef] [Green Version]
- Ticinesi, A.; Milani, C.; Lauretani, F.; Nouvenne, A.; Mancabelli, L.; Lugli, G.A.; Turroni, F.; Duranti, S.; Mangifesta, M.; Viappiani, A.; et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep. 2017, 7, 11102. [Google Scholar] [CrossRef] [Green Version]
- Shanahan, F.; Ghosh, T.S.; O’Toole, P.W. The Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome? Gastroenterology 2021, 160, 483–494. [Google Scholar] [CrossRef]
- Deleu, S.; Machiels, K.; Raes, J.; Verbeke, K.; Vermeire, S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? eBioMedicine 2021, 66, 103293. [Google Scholar] [CrossRef]
- Buttó, L.F.; Haller, D. Dysbiosis in intestinal inflammation: Cause or consequence. Int. J. Med. Microbiol. 2016, 306, 302–309. [Google Scholar] [CrossRef]
- Mirsepasi-Lauridsen, H.C.; Vallance, B.A.; Krogfelt, K.A.; Petersen, A.M. Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease. Clin. Microbiol. Rev. 2019, 32, e00060-18. [Google Scholar] [CrossRef] [Green Version]
- Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 2008, 105, 16731–16736. [Google Scholar] [CrossRef] [PubMed]
- Melgar, S.; Shanahan, F. Inflammatory bowel disease-from mechanisms to treatment strategies. Autoimmunity 2010, 43, 463–477. [Google Scholar] [CrossRef] [PubMed]
- Effenberger, M.; Reider, S.; Waschina, S.; Bronowski, C.; Enrich, B.; Adolph, T.E.; Koch, R.; Moschen, A.R.; Rosenstiel, P.; Aden, K.; et al. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. J. Crohn’s Colitis 2021, 15, 88–98. [Google Scholar] [CrossRef]
- Estevinho, M.M.; Rocha, C.; Correia, L.; Lago, P.; Ministro, P.; Portela, F.; Trindade, E.; Afonso, J.; Peyrin-Biroulet, L.; Magro, F.; et al. Features of Fecal and Colon Microbiomes Associate with Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. Clin. Gastroenterol. Hepatol. 2020, 18, 1054–1069. [Google Scholar] [CrossRef]
- Olaisen, M.; Spigset, O.; Flatberg, A.; Granlund, A.V.B.; Brede, W.R.; Albrektsen, G.; Royset, E.S.; Gilde, B.; Sandvik, A.K.; Martinsen, T.C.; et al. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment. Pharmacol. Ther. 2019, 49, 1301–1313. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Eckenberger, J.; Butler, J.C.; Bernstein, C.N.; Shanahan, F.; Claesson, M.J. Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease. Microorganisms 2022, 10, 1963. https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms10101963
Eckenberger J, Butler JC, Bernstein CN, Shanahan F, Claesson MJ. Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease. Microorganisms. 2022; 10(10):1963. https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms10101963
Chicago/Turabian StyleEckenberger, Julia, James C. Butler, Charles N. Bernstein, Fergus Shanahan, and Marcus J. Claesson. 2022. "Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease" Microorganisms 10, no. 10: 1963. https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms10101963